Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

July 23, 2020

Study Completion Date

July 23, 2020

Conditions
Liver Cancer
Interventions
BIOLOGICAL

immunotherapy with Nivolumab

After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.

PROCEDURE

Radiofrequency Ablation

The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.

Trial Locations (1)

116

Wanfang Hospital, Taipei

All Listed Sponsors
lead

Taipei Medical University WanFang Hospital

OTHER

NCT04707547 - Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy | Biotech Hunter | Biotech Hunter